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BY-NC-ND license (http://creativecomAbstract Background/Purpose: Immune dysregulation, polyendocrinopathy, enteropathy, X-
linked (IPEX) syndrome is a severe autoimmune disease that is caused by regulatory T cell defi-
ciency due to FOXP3 gene mutations. The long-term outcome can be variable depending on the
extent of tissue damage caused by autoimmunity and infections, the use of immunosuppressive
treatment or sequela of bone marrow transplantation.
Methods: We used immunohistochemical staining to analyze cell types infiltrating the tissue of
affected organs from a classic IPEX patient with a splicing mutation (c.736-2A>C) in the FOXP3
gene. Expression of transcription factors that are critical for immune responses including T-
bet, GATA-3, RORgt, and FOXP3 were evaluated in various tissue samples. For objective anal-
ysis of the distribution of different cell types in tissues, we used an automated microscope-
based image acquiring system to assess quantitatively the different cell types by investigating
the histopathological changes in the patient’s biopsy samples obtained from the intestine and
the kidneys before and after treatment.
Results: The percentages of cells expressing the TH2-associated transcription factor GATA3
were higher in the IPEX patient before treatment than in controls, suggesting that TH2-typeClinical Medicine, National Cheng-Kung University Medical College, 138 Sheng-Li Road, Tainan 704,
edu.tw (C.-C. Shieh).
.10.015
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776 C.-A. Chen et al.cells contribute to the tissue inflammation of the gut and kidneys in IPEX syndrome. Immuno-
suppressive treatment effectively decreased the number of effector cells in the kidneys and
intestine of the IPEX patient.
Conclusion: This study provides quantitative evidence that the inflamed intestinal and renal
tissues of the IPEX patient contain TH2-type immune effector cells, which decreased in number
after immunosuppressive treatment was initiated and the clinical symptoms had improved.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Immune dysregulation, polyendocrinopathy, enteropathy,
X-linked (IPEX) syndrome is a life-threatening disease that
was first described in 1982.1 It usually presents in young
infants or children and leads to severe, multiorgan auto-
immune phenomena including chronic enteropathy,
dermatitis, and endocrinopathy, such as type I diabetes
mellitus and thyroiditis. Other abnormalities frequently
observed include autoimmune cytopenia (i.e., hemolytic
anemia, thrombocytopenia, or neutropenia), nephritis,
hepatitis, and elevated levels of serum immunoglobulin (Ig)
A and E. Episodes of severe infections are often reported in
patients with this syndrome.2e4 IgG and IgM levels are
typically normal but can be slightly depressed in older in-
dividuals, probably as a result of enteric protein loss. It is a
relatively rare disorder with fewer than 160 cases described
worldwide over a 10-year period.5 Without appropriate
treatment, this syndrome is fatal in most affected children
within the first 2 years of life. Germ-line mutations in the
FOXP3 gene, a master transcriptional regulator for the
development of CD4þCD25þCD127low regulatory T cells
(Treg), were found in many male patients with the IPEX
phenotype.6,7
Tregs, a T cell subpopulation with broad inhibitory im-
mune functions, are important for maintaining self-
tolerance and immune homeostasis.8,9 The FOXP3 gene
encodes the forkhead box protein 3, a member of the
forkhead/winged-helix family of DNA-binding transcrip-
tional regulators,6 which is essential for Treg differentia-
tion.8,9 In humans, the FOXP3 gene is located on the X
chromosome at Xp11.23. Although FOXP3 gene mutations
leading to loss of function have been associated with the
syndrome, the exact immune mechanisms leading to tissue
damage in IPEX syndrome patients have rarely been inves-
tigated. In this study, we aimed to measure quantitatively
the inflammatory cell infiltrates in critical internal organs
damaged by autoimmunity in a patient with classic IPEX
syndrome, and to determine the dominant immune effector
cells in the tissues damaged by the disease.Case Report
The index case was the second child of nonconsanguineous
parents. The boy was born via cesarean delivery due to
breech presentation with a birth weight of 2950 g and
length of 51 cm. Since the age of 2 months, generalized skinscaling was present (Figure 1A), he was repeatedly hospi-
talized for pneumonia due to Staphylococcus aureus, and
chronic diarrhea leading to severe malnutrition and failure
to thrive. Endoscopy revealed a pale and fragile mucosa,
affecting the entire upper and lower gastrointestinal tract.
Histological analysis of gastrointestinal tract biopsies
demonstrated extensive villous atrophy with widespread
leukocyte infiltration. The lamina propria of the colonic
mucosa was infiltrated by lymphocytes, plasma cells, eo-
sinophils, and neutrophils. Laboratory evaluation revealed
elevated IgE levels (up to 18,000 IU/mL) but normal IgG,
IgM, and IgA. Hypoalbuminemia, possibly related to
protein-losing enteropathy, was persistently observed.
Immunological analysis using flow cytofluorometry per-
formed at the onset of diarrhea showed a normal distribu-
tion of lymphocyte subpopulations (CD3: 2829/mL; CD4:
1511/mL; CD8: 1085/mL; and CD19: 814/mL HLA-DR: 1744/
mL). In his early infancy, the patient suffered from multiple
episodes of bacterial and candida sepsis and pruritic
eczematous dermatitis. At age 1 year, type I diabetes
mellitus was diagnosed. Genomic DNA sequencing of the
FOXP3 gene revealed a splice-site mutation upstream of
exon 7 (c.736-2 A>C). Sequence analysis of the FOXP3 cDNA
demonstrated skipping of exon 7, which causes an in-frame
deletion of 27 amino acids upstream of the forkhead
domain. The same heterozygous mutation was found in the
mother. We started calcineurin inhibitor [i.e., cyclosporine
A and tacrolimus (FK506)] treatment at the age of 2 years
and 3 months resulting in improvement of the skin lesions
(Figure 1B), diarrhea, and growth retardation, and total
parenteral nutrition could be discontinued. Serial histo-
logical studies revealed a gradual improvement of the in-
flammatory lesions throughout his digestive tract. However,
renal tubular acidosis was noted at age 21/2 years.
Nephrotic syndrome due to membranous glomerulone-
phritis developed at age 71/2 years. Treatment with anti-
CD20 antibody (Rituximab) was started at the age of
7 years and 10 months in an attempt to control the
glomerulonephritis, with clinical improvement. Hemato-
poietic stem cell transplantation was refused by the family.
The patient died at age 8 years and 4 months of Strepto-
coccus pneumoniae sepsis.
Histological examination
Blocks of paraffin-embedded intestinal biopsies from the
IPEX patient and normal controls were provided by the
Department of Pathology, National Cheng Kung University
Figure 1. Clinical presentation and lack of regulatory T cells observed in the immune dysregulation, polyendocrinopathy, en-
teropathy, X-linked syndrome patient. (A) Generalized scaling of the skin and many scratching marks are observed on the face and
scalp of the patient. Similar skin lesions are found all over the body before treatment. (B) Improved skin after treatment with
tacrolimus. (C) The patient had few CD4þ FOXP3þ cells (0.3%) in the blood cells when compared with normal controls (2.7%).
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with normal gross and microscopic appearance from a pa-
tient who was evaluated for allergic intestinal inflammation
were used as comparative controls. The renal biopsy was
fixed in 10% buffered neutral formalin and embedded in
paraffin. Tissue sections (2e3 mm) were cut onto Dako
slides (Dako-Cytomation, Glostrup, Denmark), incubated at
45C overnight, and deparaffinized three times using xylene
(5 minutes, room temperature). The slides were rehydrated
in a series of ethanol solutions (100% and 95% for 2 minutes
each) and washed with Tris-buffered saline and tween
(TBST) 20, then stained with hematoxylin and eosin using
standard procedures.
Immunohistochemistry
For immunohistochemistry staining, tissue sections from
the IPEX patient and a normal control, cut on poly-L-
lysine-coated slides, were deparaffinized in xylene and
rehydrated in a series of ethanol. Antigen retrieval was
performed by microwave cooking (Sampo, 800W output)
for 2 minutes in 10mM citrate buffer (pH 6.0), and then
cooled to room temperature for 30 minutes and washed
with TBST once. The endogenous peroxidase activity was
blocked with PolyDetector Peroxidase Block solution (Bio
SB, Goleta, CA, USA) for 30 minutes at room temperature
then washed three times with TBST. Following immune
blocking with 1% bovine serum albumin for 30 minutes, theslides were incubated with primary antibodies overnight,
and the signals visualized by immunohistochemical
procedures.
Quantitative measurement of transcription factors
involved in T cell development
We used immunohistochemistry and objective quantifica-
tion to detect the different types of T helper cells in the
intestinal and kidney biopsies of the IPEX patient and of a
control with allergic intestinal inflammation.
For objective counting of different cell types in tissues,
we used a microscope-based image acquiring system that
can create large overviews of tissue specimen with high
magnification (TissueGnostics Cytometry; TissueGnostics
GmbH, Vienna, Austria) to scan the slides with high
magnification. We scanned the whole biopsy tissue and
selected at least four representative areas to analyze the
proportion of positive stained cells to avoiding the obser-
vational bias. We used computer-assisted analysis Histo-
quest software (TissueGnostics GmbH), which enhanced the
accuracy and objectiveness in histopathology to study the
expression of multiple transcription factors known to play
important roles in T cell development,10e12 using the
following antibodies for tissue staining according to the
respective manufacturers’ instructions: H-210: sc-21003
(Santa Cruz Biotechnology, Dallas, TX, USA) for T-bet,
10417-1-AP (Proteintech Group, Chicago, IL, USA) for GATA-
778 C.-A. Chen et al.3, Ab78007 (Abcam, Cambridge, UK) for RORgt and 14-4776
(eBioscience, San Diego, CA, USA) for FOXP3.
Statistical analysis
The expression level of T-bet, GATA-3, RORgt, and FOXP3 in
tissues were statistically analyzed with Student t test using
GraphPad Prism software version 5.0 (GraphPad Software,
La Jolla, CA, USA). A p value < 0.05 was considered sta-
tistically significant.
Results
Characterization of Treg deficiency
Flow cytometry data demonstrated that the IPEX patient
had few CD4þ expressing FOXP3þ lymphocytes (0.3%) in the
peripheral blood when compared with a normal control
(2.7%; Figure 1C). Immunohistochemical staining was car-
ried out to examine the percentage of FOXP3-positive
lymphocytes in the intestinal tissue of the IPEX patient in
comparison with a control who had nonspecific intestinal
inflammation. The intestinal biopsy sections from the IPEX
patient contained no FOXP3þ lymphocytes while, in the
control with nonspecific intestinal inflammation, we could
easily identify many FOXP3þ (Figure 2A). Quantitative
analysis showed that the IPEX patient expressed < 0.3%
FOXP3þ cells compared with 3% in the tissue from the
control with nonspecific intestinal inflammation
(Figure 2B).Figure 2. Markedly reduced FOXP3-positive lymphocytes in the b
polyendocrinopathy, enteropathy, X-linked syndrome. (A) Immuno
FOXP3 positive lymphocytes in the intestinal section, while the co
arrows, FOXP3-positive cells have a dark nucleus. The yellow arrow
(B) Quantitative analysis of FOXP3 positive cells in the small bowe
positive lymphocytes while the patient has < 0.3%.T cell specific transcription factors expression in
the intestinal mucosa
We then used immunohistochemical staining to quantify the
key transcription factors for T cell differentiation in the
intestine of our IPEX patient before and after calcineurin
inhibitor FK506 (tacrolimus) treatment. After treatment,
the percentage of T-bet-expressing lymphocytes was
significantly (p < 0.001) reduced (Figure 3). The TH2 cell
transcription factor GATA-3 was expressed at a higher
percentage in gut tissue of the IPEX patient than in the
control patient before treatment. However, after treat-
ment with FK506, the percentage of GATA-3 expressing
lymphocytes markedly decreased, reaching levels that
were even lower than those of the control (Figure 3). The
percentage of RORgt expressing lymphocytes was slightly
higher than that in the control before the calcineurin in-
hibitor treatment, but showed no significant change after
FK506 treatment (Figure 3).
Histological examination of renal biopsy sections
before and after immunomodulatory treatment
As the kidneys are frequently affected in patients with
IPEX (as was the case in our patient), we investigated the
immunopathology of the renal tissue to elucidate the
autoimmune-mediated tissue damage. Electron micro-
scopy revealed diffuse thickening of the glomerular base-
ment membrane and a few tubular reticular bodies in
endothelial cells representing electron dense immunelood and the intestine of a patient with immune dysregulation,
histochemistry staining for FOXP3. The IPEX patient shows no
ntrol has FOXP3 positive cells in the small bowel mucosa. Red
s indicate unstained lymphocytes (original magnification 400).
l. The control with nonspecific inflammation has 3% of FOXP3
Figure 3. Changes in the expression of T helper cell-associated transcription factors in the small bowel of the immune dysre-
gulation, polyendocrinopathy, enteropathy, X-linked syndrome patient (IPEX). (A) Sections were stained with antibodies specific for
T-bet, GATA-3, and RORgt. Red arrows indicate positive-stained cells. (B) Quantitative measurement of transcription factors
expressing cells in sections stained by immunohistochemistry. The expression of Th2-associated transcription factor GATA3 in the
IPEX patient was higher than in the control before treatment with calcineurin inhibitor, and decreasing after treatment. Th1-
associated transcription factor T-bet expression in the IPEX patient was lower than control before and after treatment. Th17-
associated transcription factor RORgt expression in the IPEX patient was also higher than in the control but showed no differ-
ence when measured before and after treatment.
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shows focal segmental expansion of mesangial matrix with
mesangial hypercellularity (Figure 4A). Because anti-CD20
monoclonal antibody (Rituximab) improved the nephritis
of the IPEX patient, we analyzed the key transcription
factors for T helper cell differentiation in the kidney of the
IPEX patient before and after Rituximab treatment
(Figure 4B). Quantification of the positively stained lym-
phocytes in the glomeruli of renal biopsy showed that
before treatment, GATA-3-expressing lymphocytes were
the major infiltrating cells, being more frequent than T-bet
or RORgt-expressing lymphocytes (Figure 4C). After Rit-
uximab treatment, the percentage of GATA-3 and RORgt-
expressing lymphocytes decreased significantly (p < 0.05),
while the percentage of T-bet-expressing lymphocytes did
not differ significantly in pre- and post-treatment
collected samples.Discussion
Regulatory T cells are indispensable for maintaining self-
tolerance and immune homeostasis.13 Treg deficiency has
been attributed to the pathogenesis of many autoimmune
diseases, including IPEX syndrome, type I diabetes, multi-
ple sclerosis, rheumatoid arthritis, inflammatory bowel
disease, and systemic lupus erythematous.14 In this study,
we evaluated a patient with a splicing mutation in the
FOXP3 gene leading to severe Treg deficiency who pre-
sented as typical IPEX syndrome. We found that the
expression of the TH2 cell-associated transcription factor
GATA-310 was higher than that of the TH1 and TH 17 cell-
associated transcription factors11,12 in intestinal and renal
tissues when measured before treatment with calcineurin
antagonists and Rituximab, respectively. Moreover, the
proportion of the TH2-associated transcription factor GATA3
Figure 4. Changes in the concentration of the T helper cell-associated transcription factor expression suggest that Th2-type and
Th17-type cells may participate in the tissue inflammation of immune dysregulation, polyendocrinopathy, enteropathy, X-linked
syndrome nephritis. (A) Electron microscopy shows a few electron-dense depositions in mesangial areas with thickening of
glomerular basement membrane (left panel), and a few tubulo-reticular bodies (arrows) in endothelial cells (central panel). The
hematoxylin and eosin stain shows segmental expansion of mesangial matrix (right panel). (B) Immunohistochemical staining
(brown staining of nuclei) for T-bet, GATA-3, and RORgt are detected within glomeruli in the renal biopsies of the IPEX patient
before and after treatment with Rituximab. (C) Quantitative assessment of glomerular cells in the renal sections described in (B).
The percentage of cells expressing GATA-3 was higher than that of T-bet and RORgt, and decreased significantly (pZ 0.002) after
treatment. The expression of T-bet did not differ before and after treatment. The percentage of RORgt expressing cells within
glomeruli also decreased significantly (p < 0.0001) after treatment.
780 C.-A. Chen et al.decreased significantly after effective immunosuppressive
therapy. These observations suggest that TH2-type cells are
important effector cells responsible for immune-mediated
damage of the intestine and kidneys in IPEX syndrome.
The IPEX syndrome is caused by mutations in the FOXP3
gene that is located on the X chromosome (Xq11.23) and
consists of 11 coding exons (exons 1e11) and three non-
coding exons.6,15 Phenotypically, most patients with caus-
ative FOXP3mutations have classic IPEX syndrome. To date,
> 30 unique FOXP3 mutations have been identified inpatients with IPEX, mainly clustering at the beginning and
in the third part of the genedmost of which result in a
change in the amino acid sequence in the DNA-binding
forkhead domain of the FOXP3 protein.7,16,17 Our pa-
tient’s genomic DNA sequencing of the FOXP3 gene
revealed a novel A > C mutation in the invariant splice site
upstream of exon 7 (c.736-2 A>C) resulting in skipping of
exon 7 and the in-frame deletion of 27 amino acids up-
stream of the DNA binding domain, which encodes part of
the leucine zipper domain and is expected to interfere with
Quantitative analysis of tissue inflammation in IPEX 781protein homodimerization and its transcriptional activ-
ity.18,19 Although we did not directly measure the stability
of the produced protein in this study, the absence of FOXP3
protein in the patient’s lymphocytes suggests that the
truncated protein is unstable.
Previous descriptions of immune-mediated tissue dam-
age in IPEX patients focused mainly on endocrine organs
and the intestinal tract.3 It was suggested that TH1 and
TH17 cells functioned as mediators of tissue damage and
autoimmunity leading to immune dysregulation and lym-
phocytic infiltrates of major organ systems characteristic
for IPEX.20,21 In addition, Tregs have been shown to be
important for the maintenance of peripheral B-cell toler-
ance in humans.22 However, almost one-third of IPEX pa-
tients have renal involvement with histological changes
ranging from immune complex deposition to interstitial
nephritis.17,23,24 It is unclear whether the renal manifesta-
tions are secondary to the treatment, which often include
drugs with renal toxicity or are related to the disease itself.
However, IPEX patients with renal disease prior to the use
of immunosuppressive drugs had been observed.24 It has
been reported that IPEX patients who underwent successful
bone marrow transplants showed rapid improvement of
their renal disease with normalization of renal function
while the outcome in patients treated only with calcineurin
inhibitors is less favorable.23,24 In this study, we found that
before treatment, TH2-type cells were the major infil-
trating cells in the glomeruli, with a higher proportion than
that of TH1 and TH17 cells. Interestingly, after treatment
with Rituximab both TH2-type and TH17-type cells signifi-
cantly decreased while the proportion of TH1 cells did not
change significantly, suggesting a role of auto-antibody in
the pathogenesis of renal disease in IPEX.
The clinical presentation of IPEX, which includes
elevated serum IgE and dermatitis lesions similar to atopic
dermatitis implicate the role of TH2-type cells in the dis-
ease. T helper cells have been demonstrated to be critical
for B cell activation and antibody production. In mice, TH1
cells preferentially induce IgG2a, while TH2 cells induce
IgG1 and IgE secretion.25 Our findings that TH2-type cells
are the major effector cells in the intestine and the kidneys
suggest that autoantibody production might be among the
important mechanisms of autoimmune tissue damage. The
presence of tubule-reticular inclusion bodies, a character-
istic finding in lupus nephritis,26 in the kidney biopsies from
the IPEX patient (Figure 4A) also suggests that a common
mechanism involving autoantibody and immune complex
deposition may contribute to the characteristic renal dis-
ease of IPEX syndrome, similar to the renal damage in lupus
nephritis.
Three primary immunodeficiency diseases (IPEX, Wis-
kotteAldrich syndrome, and Omenn syndrome) are re-
ported to be associated with high levels of IgE and
defective Treg cell number or function.27 The uncontrolled
TH2 type immune responses not only dominate the auto-
immune responses in the target tissues but also hinder the
host from mounting effective immune responses to invading
microorganisms requiring other types of immune defense. A
shared deregulation of immune responses may lead to the
defective immunity in these primary immunodeficiency
diseases with defective Treg functions.Glucocorticoid monotherapy or combination immuno-
suppression has been shown to be only partially effective in
controlling the autoimmune manifestations.28 Although
they are used as the first line therapy to limit progression of
organ damage, glucocorticoids complicate diabetes man-
agement and are associated with significant side effects
with long-term use in children. Other immunosuppressive
drugs thus are added onto the steroids regimens. Cyclo-
sporine and/or tacrolimus, as used in this report, have been
most commonly used in conjunction with steroids.
Like T helper cells, subpopulations of innate lymphoid
cells (ILCs) have been shown to react promptly to signals
from infection or tissue damage and produce cytokines to
direct the development of autoimmune responses.29 A
number of transcription factors including T-bet, GATA-3,
and RORgt have been shown to be expressed in ILC sub-
population and are important for the development of
ILCs.30 It is likely that the T-bet, GATA-3, and RORgt-
expressing lymphocytes we identified in this study (Figures
3 and 4) include both T cells and ILCs. Although FOXP3 has
not been shown to be expressed in ILCs, lack of FOXP3 and
hence Tregs may well affect the activity of ILCs and lead to
immune-mediated tissue damage. A recent report demon-
strated that FOXP3þ Tregs can directly inhibit a subpopu-
lation of ILCs and thereby suppress innate cell-driven
colitis.31 If and how ILCs participate in the pathogenesis
of IPEX syndrome merits further investigation.
In the clinical setting, histological examinations are
important for the understanding of the pathogenic pro-
cesses and for choosing appropriate treatments.32 Most
histologic techniques for quantitatively assess pathologic
events in histology studies randomly select areas in the
tissue and use a grading system that is more or less sub-
jective. Hence, the results heavily depend on the observer
who uses their own standard of quantitative measurement.
In this study, we selected an automated microscope-based
image acquiring system that can create large analysis of
tissue specimen with high resolution. The software we used
automatically quantifies the staining intensity of signals in
the tissue.33 This system solved the problem to quantita-
tively assess effector cells in the tissue of our IPEX patient.
Thus we were able to identify critical immune-pathogenic
changes that may well have been overlooked otherwise.
In conclusion, this study provides direct evidence that
the autoinflammation affecting the GI tract and kidneys in
our IPEX patient is caused by TH2-dominant effector
mechanisms. After immunosuppressive therapy with
tacrolimus and Rituximab or with Rituximab alone, the TH2-
type lymphocyte infiltration was suppressed and the auto-
immune tissue damage in the GI tract and the kidneys
improved. To our best knowledge this is the first direct
evidence that TH2-type lymphocytes are the major cells
infiltrating the affected tissues from IPEX patients. We
speculate that compounds targeting TH2-type cells may be
an effective therapy to target autoimmune-mediated in-
ternal organ damage of patients with IPEX.Conflicts of interest
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